Frank N. Hrisomalos, M.D., M.B.A.
Sub-Specialty:
Vitreoretinal Disease and Surgery
Practice:
Nicholas F. Hrisomalos, MD PC
317-817-1500
Services, Procedures and Patient-Care Specialties
Conditions Treated: Comprehensive medical and surgical vitreoretinal care including: Wet and Dry Macular Degeneration, Polypoidal Choroidal Vasculopathy, Diabetic Retinopathy and Diabetic Macular Edema, Retinal Vein and Artery Occlusions, Retinal Detachments, Retinal Tears and Holes, Lattice Degeneration, Macular Hole, Vitreomacular Traction, Epiretinal Membrane, Macular Telangiectasia, Central Serous Chorioretinopathy, Endophthalmitis and other bacterial, viral, and fungal eye infections, Hereditary Retinal Dystrophies and Degenerations, Retinitis Pigmentosa, Stargardt Disease, Uveitis and eye inflammation, Retinoschisis
Diagnostics: Optical Coherence Tomography (OCT), Fundus Photography (Topcon and Optos), Electroretinography, Fluorescein and ICG Angiography, B-scan Ultrasound
Procedures: Vitrectomy, Scleral Buckle, Retinal Lasers and Cryoretinopexy (freezing), Pneumatic Retinopexy, Intravitreal InjectionsEducation
B.S. in Biology with High Distinction, Indiana University Bloomington, IN 2002-2006
Honors/Awards
Chief Transitional Intern, St. Vincent Hospital, Indianapolis, IN
Chief Resident in Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
Beta Gamma Sigma
Phi Beta Kappa
Residencies
Internship in Transitional Medicine, St. Vincent Hospital, Indianapolis, IN 2011-2012
Residency in Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, 2012-2015
Fellowship
Fellowship in Vitreoretinal Disease and Surgery, Washington University in St. Louis, St. Louis, MO, 2015-2017
Board Certification
American Board of Ophthalmology, 2016
Research Studies
Dr. Hrisomalos has been a sub-investigator for the following clinical trials:
- Intravitreal Aflibercept Injection for Radiation Retinopathy. NCT01579760
- Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability,
Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects with Severe Sepsis. NCT02576457 - A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injections(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). NCT02341560